Sign In
Buy NAUT
$0.87
-0.0351 (-3.90%)
At Close: Aug 10, 2026
Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback
03:44am, Monday, 03'rd Aug 2026
NAUT is now prioritizing targeted proteoform assays after Broadscale testing failed to support its prior commercialization roadmap. But their roadmap with Voyager is clearer, although Early Access rev
Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript
01:23pm, Tuesday, 28'th Jul 2026
Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript
Nautilus Biotechnology Q2 Earnings Call Highlights
10:05am, Tuesday, 28'th Jul 2026
Nautilus Biotechnology NASDAQ: NAUT said it is shifting a significant share of its research and development resources toward proteoform applications, citing customer interest and a delay in its Broads
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
08:00am, Tuesday, 28'th Jul 2026
SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the seco
Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
08:00am, Wednesday, 08'th Jul 2026
SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will rep
3 Small-Cap Stocks to Buy Before May 15
12:00pm, Sunday, 10'th May 2026
Tom Yeung here with your Sunday Digest.
Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript
05:01pm, Tuesday, 28'th Apr 2026
Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
08:00am, Tuesday, 28'th Apr 2026
SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fir
Forget Neuralink: The Real Brain Tech Trade Has 10 Names You’ve Never Heard
12:00am, Saturday, 25'th Apr 2026
The real brain computer interface opportunity isn't in the headlines. These 10 stocks are building the systems that make it possible.
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
08:00am, Wednesday, 18'th Mar 2026
• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit • NIH-funded project leverages
Nautilus Biotechnology, Inc. (NAUT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
07:35am, Friday, 06'th Mar 2026
Nautilus Biotechnology, Inc. (NAUT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript
01:37pm, Thursday, 26'th Feb 2026
Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
04:05pm, Thursday, 19'th Feb 2026
SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company
• Buck Institute's deployment of Nautilus' instrument generates tau proteoform data, providing external validation of the company's next-generation single-molecule proteomics platform • Joint re
Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript
11:31am, Tuesday, 28'th Oct 2025
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sujal Patel - Co-Founder, CEO, President, Secretary & Director Kentaro Suzuki - Chie
